Provider Statement

This continuing education activity is provided by

Support Statement

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Activity Description

Management of patients with retinal vascular diseases utilizing intravitreal anti-vascular endothelial growth factor (VEGF) therapy has provided significant enhancements to visual acuity outcomes, but maintenance of these visual acuity gains requires frequent treatment and monitoring. The frequency of these clinical visits can be a challenge to sustain and places a considerable burden on the patient and caregivers?often resulting in undertreatment of disease due to loss of adherence. To address this unmet need, gene therapies and novel delivery systems that reduce the need for frequent treatment dosing have been developed. Gene therapies are currently being evaluated in ongoing clinical studies while the Port Delivery System (PDS) with ranibizumab was recently FDA-approved for the management of patients with neovascular age-related macular degeneration (nAMD). To achieve optimal efficacy and safety outcomes, these novel delivery modalities require unique surgical approaches for their implication into clinical practice. In this CME activity, experts in the field will discuss criteria that identify patients with nAMD as appropriate candidates for surgical delivery modalities, evaluate best practices and procedures that reduce complications when utilizing these modalities, and review appropriate techniques for the refill–exchange of the PDS with ranibizumab.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal vascular diseases.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Identify patients who would be appropriate candidates for the surgical delivery of therapies that extend treatment intervals in neovascular age-related macular degeneration (nAMD).
  • Apply the appropriate techniques into practice for the refill and exchange of the Port Delivery System with ranibizumab.
  • Incorporate practices and procedures that reduce complications when using the Port Delivery System or subretinal gene therapy for nAMD.

Activity Chair

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA


Nancy M. Holekamp, MD
Director, Retina Services
Pepose Vision Institute
St. Louis, MO


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, January 20, 2023 to January 19, 2024.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s)

Nancy M. Holekamp, MD
Royalties or Patent Beneficiary: Katalyst Surgical
Advisor: Nacuity, PolyActiva
Consultant: 4DMT, Adverum, AGTC, Bayer, Biogen, Boehringer Ingelheim, Clearside, EyePoint, Gemini, Genentech, Gyroscope, Katalyst Surgical, Nacuity, Novartis, Ocuphire, Outlook Therapeutics, Regeneron, Stealth, Vial
Speaker Contracted by Ineligible Company: Apellis, Genentech, Regeneron
Independent Research Contractor: Gemini, Genentech, Gyroscope
Individual Stocks and Stock Options: Gemini, Katalyst Surgical, Nacuity
Data Monitoring and Safety Committee: Editas, Ocuphire, Roche

Carl D. Regillo, MD, FACS
Consultant: 4DMT, Adverum, Aldeyra, Allergan, Annexon, Apellis, Aviceda, Chengdu Kanghong, Clearside, EyePoint, Genentech, Graybug, Iveric Bio, Kodiak, Lineage, Merck, NGM, Notal, Novartis, Ocugen, Regenxbio, Stealth BioTherapeutics
Independent Research Contractor: Adverum, Alderya, Allergan, Annexon, Apellis, Astellas, Chengdu Kanghong, Clearside, EyePoint, Genentech, Graybug, Iveric Bio, Kodiak, Lineage, NGM, Novartis, Opthea, Regeneron, Regenxbio

Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA,

No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *